The letter, published in the journal Pain Medicine, outlines risks
associated with forced tapering of the addictive drugs and petitions
U.S. policymakers to develop guidelines that are not "aggressive and
unrealistic."
Nearly 18 million Americans are long-term opioid users because of
chronic pain. In the wake of an opioid addiction crisis that has
claimed thousands of lives, health regulators and the medical
community have doubled down on reducing the number of opioid pills
prescribed to patients.
The U.S. Centers for Disease Control and Prevention advocates
tapering and, in some cases, discontinuing opioids in patients using
them as long-term therapy for chronic pain.
However, in their letter, Beth Darnall of Stanford University in
California and coauthors say mandated opioid tapers requiring
"aggressive" dose reductions over a defined period, even when that
period is an extended one, could be problematic.
They call for "compassionate systems for opioid tapering" in
carefully selected patients, with close monitoring and realistic
goals. They also call for "patient advisory boards . . . to ensure
that patient-centered systems are developed and patient rights are
protected."
"The assumption that forced opioid taper is reliably beneficial is
not supported by evidence, and clinical experience suggests
significant harm," said Ajay Manhapra of Yale University, who
co-authored the letter.
For example, the letter notes, rapid forced tapering can destabilize
patients, lead to a worsening of pain, precipitate severe opioid
withdrawal symptoms and cause a profound loss of function.
Some patients may seek relief by sourcing illicit, and more
dangerous, opioids, while others risk becoming "acutely suicidal",
the paper adds.
[to top of second column] |
"With the opioid tapering culture, pain specialists are making a
killing," Manhapra said. "Our clinical experience is that with rapid
tapers the healthcare costs go up due to excessive use of other
costly services like emergency rooms and spine specialists."
"Whether it's a fast taper or a slow taper, the big question is -
well, what do you do after that?" said Dr. Richard Blondell, vice
chair for addiction medicine at the University at Buffalo in New
York, who was not among the authors of the letter.
"What we really need is better science, not more politics . . . In
my experience, when you have global recommendations based on expert
opinions and you try to apply those to individual patients at
individual clinics there's a lot that gets lost in translation."
The letter petitions the U.S. Department of Health and Human
Services to consider patient data and include pain specialists when
developing opioid tapering guidelines.
Manhapra believes the onus remains on policymakers.
"It appears that the storm blew one way from 1980's to 2016 and now
it is blowing hard the other way, while we (doctors) stand
staggering at the same spot trying to take care of our patients who
are suffering," he said.
SOURCE: http://bit.ly/2T8FBbZ Pain Medicine, online November 29,
2018.
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|